CRISPR/Cas9-Mediated Gene Therapy for Glioblastoma: A Scoping Review
-
Published:2024-01-21
Issue:1
Volume:12
Page:238
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Begagić Emir1ORCID, Bečulić Hakija23, Đuzić Nermin4ORCID, Džidić-Krivić Amina5, Pugonja Ragib2ORCID, Muharemović Asja4, Jaganjac Belma6, Salković Naida7, Sefo Haso8, Pojskić Mirza9ORCID
Affiliation:
1. Department of General Medicine, School of Medicine, University of Zenica, Travnička 1, 72000 Zenica, Bosnia and Herzegovina 2. Department of Neurosurgery, Cantonal Hospital Zenica, Crkvice 67, 72000 Zenica, Bosnia and Herzegovina 3. Department of Anatomy, School of Medicine, University of Zenica, Travnička 1, 72000 Zenica, Bosnia and Herzegovina 4. Department of Genetics and Bioengineering, International Burch University Sarajevo, Francuske revolucije BB, 71000 Sarajevo, Bosnia and Herzegovina 5. Department of Neurology, Cantonal Hospital Zenica, Crkvice 67, 72000 Zenica, Bosnia and Herzegovina 6. Department of Histology, School of Medicine, University of Zenica, Travnička 1, 72000 Zenica, Bosnia and Herzegovina 7. Department of General Medicine, School of Medicine, University of Tuzla, Univerzitetska 1, 75000 Tuzla, Bosnia and Herzegovina 8. Clinic of Neurosurgery, University Clinical Center Sarajevo, Bolnička 25, 71000 Sarajevo, Bosnia and Herzegovina 9. Department of Neurosurgery, University Hospital Marburg, Baldingerstr., 35033 Marburg, Germany
Abstract
This scoping review examines the use of CRISPR/Cas9 gene editing in glioblastoma (GBM), a predominant and aggressive brain tumor. Categorizing gene targets into distinct groups, this review explores their roles in cell cycle regulation, microenvironmental dynamics, interphase processes, and therapy resistance reduction. The complexity of CRISPR-Cas9 applications in GBM research is highlighted, providing unique insights into apoptosis, cell proliferation, and immune responses within the tumor microenvironment. The studies challenge conventional perspectives on specific genes, emphasizing the potential therapeutic implications of manipulating key molecular players in cell cycle dynamics. Exploring CRISPR/Cas9 gene therapy in GBMs yields significant insights into the regulation of cellular processes, spanning cell interphase, renewal, and migration. Researchers, by precisely targeting specific genes, uncover the molecular orchestration governing cell proliferation, growth, and differentiation during critical phases of the cell cycle. The findings underscore the potential of CRISPR/Cas9 technology in unraveling the complex dynamics of the GBM microenvironment, offering promising avenues for targeted therapies to curb GBM growth. This review also outlines studies addressing therapy resistance in GBM, employing CRISPR/Cas9 to target genes associated with chemotherapy resistance, showcasing its transformative potential in effective GBM treatments.
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference121 articles.
1. Begagić, E., Pugonja, R., Bečulić, H., Čeliković, A., Tandir Lihić, L., Kadić Vukas, S., Čejvan, L., Skomorac, R., Selimović, E., and Jaganjac, B. (2023). Molecular Targeted Therapies in Glioblastoma Multiforme: A Systematic Overview of Global Trends and Findings. Brain Sci., 13. 2. Reclassification of Glioblastoma Multiforme According to the 2021 World Health Organization Classification of Central Nervous System Tumors: A Single Institution Report and Practical Significance;Stoyanov;Cureus,2022 3. A Critical Overview of Targeted Therapies for Glioblastoma;Jain;Front. Oncol.,2018 4. Tatebayashi, K., Nakayama, N., Sakamoto, D., Iida, T., Ono, S., Matsuda, I., Enomoto, Y., Tanaka, M., Fujita, M., and Hirota, S. (2023). Clinical Significance of Early Venous Filling Detected via Preoperative Angiography in Glioblastoma. Cancers, 15. 5. Angom, R.S., Nakka, N.M.R., and Bhattacharya, S. (2023). Advances in Glioblastoma Therapy: An Update on Current Approaches. Brain Sci., 13.
|
|